00:19 , Jul 31, 2019 |  BC Extra  |  Clinical News

July 30 Clinical Quick Takes: Biogen, Alkermes MS candidate superior to Tecfidera; plus Amgen, Lilly and more

Biogen, Alkermes Phase III MS candidate beats Tecfidera  Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) said diroximel fumarate (BIIB098) met the primary endpoint in the Phase III EVOLVE-MS-2 trial: superiority to Biogen’s Tecfidera dimethyl fumarate...
20:51 , Jul 25, 2019 |  BC Extra  |  Company News

As Vertex broadens remit, Leiden handing baton to Kewalramani

As Vertex continues to push its pipeline beyond cystic fibrosis, it will do so with a new president and CEO at the helm. Chairman, President and CEO Jeffrey Leiden will step down from his position...
22:15 , Jun 17, 2019 |  BC Extra  |  Company News

Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model

The most recent long-term data for bluebird bio's Zynteglo β thalassemia gene therapy show that about 80% of patients could hit payment milestones based on details the biotech disclosed about its outcomes-based pricing model on...
00:28 , Jun 7, 2019 |  BioCentury  |  Product Development

How early biomarkers and constant iteration fuel Vertex's R&D efficiency

As Vertex prepares its fourth NDA for a cystic fibrosis drug in six years, EVP of Global Research and CSO David Altshuler credits the biotech’s R&D efficiency to a focus on agents that show more...
20:42 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

CRISPR, Vertex dose first β-thalassemia patient, begin enrolling sickle cell patients in Phase I trials of CRISPR therapy

CRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) dosed the first patient in a Canadian and European Phase I/II trial of CTX001 to treat transfusion-dependent β-thalassemia, and enrolled the first patient in a U.S....
01:14 , Jan 25, 2019 |  BC Week In Review  |  Company News

Vertex builds CRISPR toolbox with Merck KGaA deal

In its latest move to build its gene editing capabilities, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in-licensed from Merck KGaA (Xetra:MRK) rights to two DNA damage response (DDR) inhibitors for gene editing applications. While Merck has been...
19:57 , Jan 24, 2019 |  BC Extra  |  Company News

Vertex builds CRISPR toolbox with Merck KGaA deal

In its latest move to build its gene editing capabilities, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in-licensed from Merck KGaA (Xetra:MRK) rights to two DNA damage response (DDR) inhibitors for gene editing applications. While Merck has been...
03:40 , Jan 18, 2019 |  BC Innovations  |  Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
18:14 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

FDA lifts hold on IND for CRISPR's sickle cell trial

CRISPR Therapeutics AG (NASDAQ:CRSP) and partner Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said FDA lifted a clinical hold on an IND for a Phase I/II trial of gene therapy CTX001 to treat sickle cell disease. Vertex declined...
18:15 , Oct 11, 2018 |  BC Extra  |  Clinical News

FDA lifts hold on IND for CRISPR's sickle cell trial

CRISPR Therapeutics AG (NASDAQ:CRSP) and partner Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said late Wednesday that FDA lifted a clinical hold on an IND for a Phase I/II trial of gene therapy CTX001 to treat sickle cell...